The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract, valued at $6,172.15, to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of fluticasone-salmeterol 230-21 12GM, a pharmaceutical product, with a period of performance through December 6, 2024. This award is part of Dakota Drug, Inc.'s larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT Generation V Program, valued at $999,999,999.00, which allows the company to provide a range of pharmaceutical products, medical supplies, and healthcare equipment to support U.S. Armed Forces medical operations. The contract has no set-aside designation, indicating Dakota Drug, Inc.'s competitive standing in the federal marketplace.
Generated 3/6/25, 9:45 AM